AUTHORS
Michael Vincent Gonzalez, PhD, MSc, Vikas Arige, PhD2, Katherine Shona Forsyth, PhD3, Melanie D Mumau, PhD4, Joseph Zinski, PhD5, Flore Castellan, PhD6, Abiola Irvine, BS7, Ira Miller8, Bridget Austin, MS9, Criswell Lavery10, David Wu, MD, PhD11, David Beck, MD, PhD12, David Yule, PhD13, Joshua D Brandstadter, MD,PhD,MSc14, David Fajgenbaum, MD, MBA, MSc15
AFFILIATIONS
1 Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 University of Rochester Medical Center, Rochester, New York, United States
3 Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 NYU Grossman School of Medicine, New York City, New York, United States
7 Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 The Ohio State University School of Medicine, Colombus, Ohio, United States
9 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 Create Motion Center, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, United States
11 UW Medicine, University of Washington, Seattle, Washington, United States
12 NYU Grossman School of Medicine, New York City, New York, United States
13 University of Rochester Medical Center, Rochester, New York, United States
14 Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
15 Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
Background: Idiopathic multicentric Castleman disease (iMCD) is a rare, immunological disorder with significant morbidity and mortality, yet its underlying etiology remains poorly understood. Several candidate somatic and germline variants have been reported in individual iMCD patients, however these prior studies have been limited by small sample sizes and other methodological constraints, and importantly, did not identify variants in more than one patient. Here, we performed germline and somatic genomic analyses in a large iMCD cohort to identify potential genetic drivers.
Methods: We performed whole-exome sequencing on peripheral blood mononuclear cells (PBMCs) from 225 iMCD patients, 76 unaffected family members, and 6 unrelated healthy controls. For a subset of 62 of these iMCD patients, paired lymph node tissue was also sequenced to identify somatic variants, using matched PBMC DNA as the germline reference. Sequencing reads were mapped to GRCh38 using the BWA aligner, and variants were called using the Genome Analysis Toolkit (GATK) best practices. ANNOVAR was used for variant annotation. Germline and somatic variants were filtered by sequencing depth, protein-altering consequence, and predicted deleteriousness (≥5 of 7 algorithms). Germline variants were restricted to a gnomAD allele frequency ≤1%, whereas somatic variants additionally required a VAF >5% and gnomAD allele frequency ≤0.01%. Candidate germline and somatic variants were evaluated for functional significance in iMCD.
Prioritized candidate variants selected for functional validation were generated by site-directed mutagenesis in an IP3R3 expression plasmid. Stable cell lines expressing either wild-type or mutant IP3R3 were generated in a CRISPR-modified HEK-293 cell line previously engineered to lack all three native ITPR genes. Channel function was assessed using fura-2/AM fluorescence Ca²⁺ imaging in intact cells and IP₃-evoked Ca²⁺ release assays in permeabilized cells.
Results: Germline whole-exome sequencing identified 7,179 rare, predicted pathogenic variants unique to iMCD patients, representing 4,911 genes. Gene-based burden analysis identified intracellular Ca2+ signaling as one of the highest-ranked biological pathways (4 of 11,038 pathways; FDR = 4.85 × 10⁻²⁵; 1.76-fold enrichment). Consistent with this finding, 24 of 225 (10.7%) iMCD patients harbored a rare predicted damaging germline variant in one of four intracellular Ca2+ signaling genes, including RYR1 (12 patients), RYR3 (7), PIEZO1 (4), and ITPR3 (3). Independently, somatic sequencing identified 6,914 rare, predicted pathogenic variants affecting 4,680 genes. Notably, 20 of 62 (32%) iMCD patients harbored a rare predicted pathogenic somatic variant in one of the four intracellular Ca2+ signaling genes, including RYR3 (9 patients), ITPR3 (8), RYR1 (8), and PIEZO1 (5). Together, the independent germline and somatic analyses converged on dysregulated intracellular Ca2+ signaling as a shared pathogenic mechanism, leading us to prioritize two patient-derived somatic ITPR3 variants (D203N and V432M) for functional validation.
Single-cell Ca2+ imaging assays revealed that IP3-evoked Ca2+ release was significantly higher at lower physiological IP3 concentrations in both mutants compared to wild-type IP3R3. Additionally, in permeabilized cell assays, IP3-evoked robust Ca2+ release from mutant IP3R3-expressing cells compared to wild-type cells. Together, these results indicate that the IP3R3 D203N and V432M mutations identified in iMCD are gain-of-function (GoF) mutations, which could explain the phenotype observed in iMCD.
Conclusions: Complementary germline and somatic genomic analyses converged on dysregulated intracellular Ca2+ signaling as a potential pathogenic mechanism in iMCD. Functional characterization of two patient-derived somatic ITPR3 variants demonstrated GoF Ca2+ channel activity, providing mechanistic support for aberrant Ca2+ signaling as a driver of immune dysregulation, given that Ca2+ signaling is critical for T cell and other immune cell activation. Ongoing studies are focused on identifying the lymph node cell populations harboring these deleterious somatic variants and the underlying molecular mechanism underlying iMCD. Together, these findings identify dysregulated intracellular Ca²⁺ signaling as a candidate pathogenic mechanism in iMCD and provide a strong rationale for further investigation of calcium signaling as a therapeutic strategy.
DISCLOSURES
Michael Vincent Gonzalez, PhD, MSc: No relevant conflicts of interest to declare.